Demonstrates limited metabolic benefit and mild cardiac hypertrophy following genetic LMPTP loss in mice, suggesting off-target actions of pharmacological inhibitors.
Inhibition of LMPTP with a small-molecular inhibitor, Cmpd23, improves glucose tolerance in mice as reported earlier. However, genetic deficiency of the LMPTP gene, Acp, has limited effects on glucose metabolism but leads to mild cardiac hypertrophy in mice. The findings suggest the potential off-target effects of Cmpd23 and call for reevaluation of LMPTP as a therapeutic target for the treatment of insulin resistance and type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Jensen-Cody et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: